

Original article

# Safety and Efficacy of New Biodegradable Polymer-based Sirolimus-Eluting Stents in a Preclinical Model



Armando Pérez de Prado,<sup>a,\*</sup> Claudia Pérez Martínez,<sup>a</sup> Carlos Cuellas Ramón,<sup>a</sup> Marta Regueiro Purriños,<sup>a</sup> María López Benito,<sup>a</sup> José Manuel Gonzalo Orden,<sup>a</sup> José Antonio Rodríguez Altónaga,<sup>a</sup> Rodrigo Estévez Loureiro,<sup>a</sup> Tomás Benito González,<sup>a</sup> David Viñuela Baragaño,<sup>a</sup> María Molina Crisol,<sup>b</sup> Marc Amorós Aguilar,<sup>b</sup> Isabel Pérez Serranos,<sup>b</sup> Arnau Vidal Parreu,<sup>b</sup> Ana Benavides Montegordo,<sup>b</sup> Luis Duocastella Codina,<sup>b</sup> and Felipe Fernández Vázquez<sup>a</sup>

<sup>a</sup> Grupo Cardiovascular (HemoLeon), Fundación Investigación Sanitaria en León y del Instituto de Biomedicina (IBIOMED), Universidad de León, Hospital Universitario de León, León, Spain

<sup>b</sup> Life Vascular Devices (LVD) Biotech, iVascular, Barcelona, Spain

Article history:

Received 12 November 2016

Accepted 28 February 2017

Available online 21 June 2017

Keywords:

Preclinical model  
Drug-eluting stent  
Restenosis  
Vascular healing

ABSTRACT

**Introduction and objectives:** New drug-eluting stents (DES) designed to overcome the limitations of existing devices should initially be tested in preclinical studies. Our objective was to analyze the safety and efficacy of new biodegradable polymer-based DES compared with bare-metal stents (BMS) and commercially available DES in a model of normal porcine coronary arteries.

**Methods:** We randomly implanted 101 stents (BMS and biodegradable polymer-based sirolimus-eluting stents: 3 test stent iterations [BD1, BD2, and BD3], Orsiro, Biomime and Biomatrix) in the coronary arteries of 34 domestic pigs. Angiographic and histomorphometric studies were conducted 1 month (n = 83) and 3 months (n = 18) later.

**Results:** The stents were implanted at a stent/artery ratio of  $1.31 \pm 0.21$ , with no significant differences between groups. At 1 month, the new test stents (BD1, BD2 and BD3) showed less late loss and angiographic restenosis, as well as lower histologic restenosis and neointimal area ( $P < .0005$ ), than the BMS. There were no differences in endothelialization, vascular injury, or inflammation between the new test stents and BMS, although the new stents showed higher fibrin deposition ( $P = .0006$ ). At 3 months, all these differences disappeared, except for a lower neointimal area with the new BD1 stent ( $P = .027$ ). No differences at any time point were observed between the new test stents and commercially available controls.

**Conclusions:** In this preclinical model, the new biodegradable polymer-based DES studied showed less restenosis than BMS and no significant differences in safety or efficacy vs commercially available DES.

© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

## Seguridad y eficacia de nuevos modelos de stents liberadores de sirolimus con polímero biodegradable en el modelo preclínico

RESUMEN

**Introducción y objetivos:** Los nuevos stents farmacológicos (SFA), diseñados para solventar las limitaciones de los existentes, han de someterse inicialmente al análisis preclínico. El objetivo es analizar la eficacia y la seguridad de nuevos SFA con polímero biodegradable en comparación con stents convencionales (SC) y SFA comercializados en el modelo de arteria coronaria sana porcina.

**Métodos:** Se implantaron aleatoriamente 101 stents (SC y stents liberadores de sirolimus con polímero biodegradable: 3 formulaciones test [BD1, BD2 y BD3], Orsiro, Biomime y Biomatrix) en las arterias coronarias de 34 cerdos domésticos. Se completó estudio angiográfico e histomorfométrico al mes (n = 83) y a los 3 meses (n = 18).

**Resultados:** Los stents se implantaron en proporción stent/arteria de  $1,31 \pm 0,21$ , sin diferencias entre grupos. Al mes, los nuevos stents (BD1, BD2 y BD3) mostraron menos pérdida tardía y reestenosis angiográfica, así como menor área neointimal y reestenosis histológica ( $p < 0,0005$ ) que los SC. No se observaron diferencias significativas entre los nuevos stents y los SC en endotelización, daño vascular o inflamación; solo se encontró mayor persistencia de fibrina en los nuevos ( $p = 0,0006$ ). A los 3 meses, todas estas diferencias desaparecieron, excepto una menor área neointimal con el nuevo stent BD1 ( $p = 0,027$ ). No hubo diferencias en ningún parámetro al mes ni a los 3 meses entre los nuevos stents y los comercializados.

Palabras clave:

Modelo preclínico  
Stent farmacológico  
Reestenosis  
Reparación vascular

\* Corresponding author: Servicio de Cardiología Intervencionista, Hospital Universitario de León, Altos de Nava s/n, 24008 León, Spain.  
E-mail address: [aperez@secardiologia.es](mailto:aperez@secardiologia.es) (A. Pérez de Prado).

**Conclusiones:** En este modelo preclínico, los nuevos SFA con polímero biodegradable estudiados presentan menos reestenosis que los SC, sin diferencias significativas en seguridad y eficacia respecto a SFA comercializados.

© 2017 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

### Abbreviations

BMS: bare-metal stents  
DES: drug-eluting stents  
MLD: minimal luminal diameter

## INTRODUCTION

Drug-eluting stents (DES) have consistently demonstrated lower rates of revascularization than bare-metal stents (BMS) in a wide range of clinical situations<sup>1</sup> and thus their use has become widespread, far surpassing that of BMS in Spain.<sup>2</sup> The risk of late thrombosis of first-generation DES has been a serious cause of concern.<sup>3</sup> This phenomenon has been associated with the deleterious effect of the drug, the drug delivery polymer, the stent platform, or a combination of these in the vessel wall, which leads to incomplete endothelialization and persistent hypersensitivity and inflammatory reactions.<sup>4–8</sup>

New-generation DES have demonstrated much lower rates of late thrombosis,<sup>9,10</sup> which is probably associated with the use of improved polymers. The use of biodegradable polymers has demonstrated an excellent safety profile in preclinical studies<sup>12</sup> and clinical studies.<sup>13–15</sup> Although these advances are very important, unwanted phenomena persist, such as the appearance of neosclerosis,<sup>16</sup> which has prompted the development of new devices that eliminate all such problems.

Preclinical models have demonstrated usefulness in analyzing differences between new devices because the sequence of biological events associated with arterial repair is similar to that in humans.<sup>17</sup> The porcine model of healthy coronary artery has been recommended by consensus to assess biological responses after the use of coronary devices.<sup>18–21</sup>

The aim of this study was to assess the safety and efficacy of 3 new biodegradable polymer-based sirolimus-eluting stent designs in a preclinical porcine model.

## METHODS

### Animal Model

This randomized controlled experimental trial with a final blind analysis used 34 Large White domestic pigs aged 2 to 3 months old. All procedures were conducted in accordance with Spanish legal regulations (Royal Decree 53/2013, 1 February, on basic standards for the protection of experimental animals) and European Directive 2010/63EC. The study was approved by the local ethics committee prior to its inception. The randomization method involved the stratified allocation of major coronary arteries so that each type of stent was implanted in the same number of arteries. The predetermined follow-up points were at 1 month (n = 28) and 3 months (n = 6).


Aspirin (325 mg) and clopidogrel (300 mg) were administered 24 hours before the procedure. The anesthesia protocol and surgical preparation have been previously described.<sup>19</sup> The animals received anticoagulant therapy with 5000 IU of unfractionated

heparin. To implant the devices at a stent/artery ratio > 1.2, we selected the best location out of 3 epicardial coronary arteries after the administration of intracoronary nitroglycerin.

### Devices Analyzed

In this study, the following devices were used:

- Control BMS (n = 27): Conventional bare-metal stent (iVascular), L605 chromium-cobalt alloy, strut thickness 80  $\mu\text{m}$ . The stent is constructed of 8 crowns joined by 3 rows of nonconcatenated connectors that form a discontinuous sinusoidal structure to provide better drug distribution.
- SFA1, BD1 (n = 32): Based on BMS, coated abluminally with 4 to 5  $\mu\text{m}$  biodegradable poly(D,L)-lactic-co-glycolic polymer, loaded with 1.0  $\mu\text{g}/\text{mm}^2$  of sirolimus, with a delivery system that allows more than 60% of the drug to be released within 30 days (Figure 1).
- SFA2, BD2 (n = 6): A variant of SFA1 with 1.4  $\mu\text{g}/\text{mm}^2$  sirolimus.
- SFA3, BD3 (n = 3): A variant of SFA1 with a slower release profile, with more than 40% of the drug released within 30 days.
- SFA4 (n = 5): Commercially available DES with Biomatrix biodegradable polymer (Biosensors Interventional Technologies,



**Figure 1.** Structure of the BD1 drug-eluting stent, with a design optimized to allow more uniform drug release. Optical microscopy image (A) and high definition image (B) obtained using the QSix system (Sensofar, Barcelona, Spain).

Singapor), strut thickness 120  $\mu\text{m}$ , loaded with 15.6  $\mu\text{g}/\text{mm}$  biolimus in an abluminal matrix of 10  $\mu\text{m}$  degradable poly(D, L)-lactate.

- SFA5 (n = 16): Commercially available DES with Biomime biodegradable polymer (Meril Life Sciences, India), strut thickness 65  $\mu\text{m}$ , loaded with 1.25  $\mu\text{g}/\text{mm}^2$  sirolimus, with a circumferential degradable matrix of 2  $\mu\text{m}$  of poly(L)-lactate and poly(L)-glycolate.
- SFA6 (n = 8): Commercially available DES with Orsiro biodegradable polymer (Biotronik, Germany), strut thickness 61  $\mu\text{m}$ , loaded with 1.4  $\mu\text{g}/\text{mm}^2$  sirolimus, with a circumferential degradable matrix of 7.5  $\mu\text{m}$  of poly(L)-lactate.

All materials were provided by iVascular, including DES 1, DES 2, and DES 3, which are still not commercially available. The study was designed in conjunction with iVascular, whereas the analysis and interpretation of the results were conducted independently of the company. The sample size and number of stents included in the study were calculated according to consensus documents on preclinical stent analysis.<sup>20</sup>

### Angiographic Analysis

After the stents were implanted, coronary angiography was repeated to determine intrastent minimal luminal diameter (MLD). At 1 month (in all animals, n = 34) and at 3 months (in those scheduled for follow-up at this point, n = 6), a new follow-up coronary angiography was conducted to assess MLD during follow-up. The MLD and reference diameters (mean diameter of the segments located in the proximal and distal 5 mm of the stent) were calculated using the Medis QCA-CMS automated quantitative coronary angiography analysis software package, version 6.1. We calculated the following angiographic restenosis parameters:

- Late loss = initial MLD – follow-up MLD.
- Percentage of angiographic restenosis =  $(1 - [\text{initial MLD}/\text{reference diameter}]) \times 100$ .

### Histological Analysis

After completing follow-up, the animals were killed (n = 28 at 1 month; n = 6 at 3 months) and histological analysis was performed as previously described.<sup>19</sup> The arteries were analyzed

histomorphometrically using an Olympus PROVIS AX70W digital microscope (Tokyo, Japan) paired with Nikon DXM 1200W digital camera and the ImageJ-NIH Image 1 POINT 4 software package (National Institute of Health, United States). Planimetry was used to determine the luminal area and the internal elastic membrane area and thus calculate the restenosis variables defined by histology:

- Neointimal area = internal elastic area – luminal area.
- Percentage of stenosis by histology =  $(1 - [\text{luminal area}/\text{internal elastic area}]) \times 100$ .

In terms of safety, the histological analysis was based on semiquantitative analysis of 4 parameters<sup>18</sup> (Table 1): the degree of vascular injury (injury score), inflammation intensity, persistent fibrin deposition, and the degree of re-endothelialization calculated as the approximate percentage of luminal surface covered by endothelial cells. According to the amount of surface area covered by endothelial cells 1 month after implantation, an additional parameter was defined: complete endothelialization, which was at least 95% of the luminal surface covered by these cells.<sup>8</sup> Stents with an injury score > 2 were excluded from the final analysis because they can have nonspecific responses in the histology of the arterial wall.

### Statistical Method

Values are expressed as percentages and as mean  $\pm$  standard deviation, depending on the type of variable. Semiquantitative variables, such as the safety scores in histopathological analysis, are expressed as mean  $\pm$  standard deviation (the most common form in previous publications) and as percentages (recommended by consensus documents for preclinical stent studies<sup>20</sup>).

Differences between the mean of the groups were analyzed using the Student *t* test and analysis of the variance. For multiple comparisons, a post hoc analysis was conducted using the Dunnett method for comparison with the control BMS and using the Tukey method for comparison of all groups. Semiquantitative variables were analyzed using the chi-square test or the Fisher exact method. To assess the possible influence of different variables (stent/artery ratio, treated artery, stent type, and injury score) on the final results of angiographic and histological stenosis, a multivariate linear regression analysis was conducted that included, in addition to the aforementioned variables, the type of stent (BMS or DES). The variables were entered into the model as a block with an input *P* value of .05 and an output *P* value of 0.1. All

**Table 1**  
Histologic Injury Score for Safety

	Grade 0	Grade 1	Grade 2	Grade 3
Injury score	No injury to IEL or media	IEL lacerated; media compressed	IEL and media lacerated; EEL intact	Break in all layers; adventitia involved
Degree of inflammation	Absent	Light lymphohistiocytic infiltrate surrounding the stent	Noncircumferential, at least moderate to dense cellular aggregate around the stent	Circumferential, dense cellular aggregate around the stent
Fibrin deposition	Absent	Moderate deposition around the stent involving < 1/4 of the artery circumference	Moderate deposition around the stent involving > 1/4 of the artery circumference or heavy deposition around and between the stents involving < 1/4 of the artery circumference	Heavy deposition involving > 1/4 artery circumference
Degree of re-endothelialization	Approximate percentage of luminal area covered by endothelial cells Complete endothelialization: at least 95% of the luminal area covered by endothelial cells			

**Table 2**  
Angiographic Results at 1 Month

	BMS (n = 12)	BD1 (n = 29)	BD2 (n = 4)	BD3 (n = 6)	Biomatrix (n = 4)	Biomime (n = 14)	Orsiro (n = 7)	P <sup>*</sup>
Late loss, mm	1.49 ± 0.70	0.87 ± 0.44	0.79 ± 0.35	1.00 ± 0.53	0.67 ± 0.57	0.90 ± 0.34	1.04 ± 0.42	< .0001
Stenosis, %	32.70 ± 19.04	12.33 ± 13.86	11.29 ± 11.99	18.80 ± 22.65	9.35 ± 6.24	10.74 ± 10.26	4.20 ± 5.45	< .0001

BMS, bare-metal stent; DES, drug-eluting stent.

Data are expressed as mean ± standard deviation.

\* BMS vs DES.

analyses were conducted with the JMP v10 statistical software package (SAS Institute Inc.; Cary, North Carolina, United States) using a *P* value < .05 as a cutoff for statistical significance.

## RESULTS


We implanted 101 of the 102 planned stents (1 BMS was not implanted because the device was not available at the time), overdilated to a mean stent/artery ratio of  $1.31 \pm 0.21$ , with no differences between stents. All animals completed the planned follow-up and the angiographic studies were performed without incident; however, 1 animal experienced cardiac arrest after anesthesia induction. Histological analyses were performed without incident. All treated segments were permeable. Eight stents (2 BMS, 2 BD1, 2 BD2, 1 BD3, and 1 Biomatrix) were excluded from the final analysis because they had an injury score > 2. Angiographic analysis could not be completed in 6 stents because of the presence of overlapping branches in the segment in 1 case (Orsiro), inadequate

opacification in 2 cases (BD1 and Biomime), and in the 3 stents of the animal that died.

## Analysis of Antirestenotic Effectiveness

The angiographic results at 1 month are shown in Table 2. Late loss and stenosis were significantly lower for all the DES than for the control BMS ( $P < .0001$  for both variables). Late loss ( $P = .0004$ ) and angiographic stenosis ( $P < .0001$ ) were lower for the new DES (BD1, BD2, and BD3) than for the BMS, but no differences were found vs the commercial DES. At 3 months, angiography was repeated in the 6 scheduled animals and the differences between DES (BD1, BD3, Biomime) and the control BMS disappeared; there was a reduction of stenosis vs the results at 1 month, which was particularly marked for the BMS (−15.3%), but was also evident for the Biomime (−6.7%) and BD1 (−0.6%).

The histopathological results at 1 month are shown in Table 3 and Figure 2. Neointimal area and stenosis were lower with DES



**Figure 2.** Histologic results at 1 month. A: conventional stent. B: BD1 drug-eluting stent. C: commercially available Orsiro drug-eluting stent. D: commercially available Biomime drug-eluting stent.

**Table 3**  
Histological Results at 1 Month

	BMS (n = 10)	BD1 (n = 25)	BD2 (n = 4)	Biomatrix (n = 4)	Biomime (n = 12)	Orsiro (n = 8)	P*
Neointimal area, mm <sup>2</sup>	3.20 ± 1.06	1.83 ± 0.67	2.54 ± 1.42	1.61 ± 0.67	1.46 ± 0.65	1.59 ± 0.48	< .0001
Area of stenosis, %	53.96 ± 12.35	31.78 ± 11.16	36.15 ± 20.20	26.37 ± 12.27	28.80 ± 13.32	29.78 ± 8.37	< .0001
Endothelial area, %	98.17 ± 1.63	96.36 ± 3.41	91.42 ± 8.18	100	96.38 ± 3.32	93.63 ± 1.30	.075
Complete endothelialization > 95%	90	52	50	100	50	0	.007
Injury score	0.93 ± 0.33	0.60 ± 0.42	1.09 ± 0.54	0.41 ± 0.47	0.46 ± 0.23	0.51 ± 0.24	.011
Injury score ≥ 1	70	12	50	25	0	0	< .0001
Inflammation score	0.61 ± 0.20	0.46 ± 0.18	0.73 ± 0.72	0.40 ± 0.13	0.41 ± 0.18	0.52 ± 0.07	.102
Inflammation score ≥ 1	0	0	25	0	0	0	.555
Fibrin score	0.53 ± 0.48	1.21 ± 0.45	1.04 ± 0.70	1.00 ± 0.71	1.35 ± 0.43	1.46 ± 0.43	< .0001
Fibrin score ≥ 1	30	92	50	75	100	100	< .0001

BMS, bare-metal stent; DES, drug-eluting stent.

Data are expressed as percentage or mean ± standard deviation.

\* BMS vs DES.


than with BMS ( $P < .0001$  for both variables). Neointimal area ( $P = .0004$ ) and area of stenosis ( $P < .0001$ ) were lower with the new DES than with BMS, but no differences were found vs commercial DES. Histological restenosis was lower at 3 months (Figure 3 and Table 4) than at 1-month follow-up. Neointimal area was lower with DES than with BMS ( $P = .012$ ), especially between BD1 and BMS ( $1.07 \pm 0.44 \text{ mm}^2$  vs  $2.63 \pm 1.02 \text{ mm}^2$ ;  $P = .027$ ). However, values were worse with BD3 than with BD1 ( $1.07 \pm 0.44 \text{ mm}^2$  vs  $1.66 \pm 0.40 \text{ mm}^2$ ;  $P = .059$ ). The results were similar regarding stenosis ( $41.30 \pm 7.28\%$  vs  $24.68 \pm 8.99\%$ ;  $P = .070$ ).

We performed multivariate analysis and the model with the greatest predictive power showed an independent association between stenosis and a higher injury score ( $B = 18.43$ ; 95% confidence interval, 12.02–24.84;  $P < .0001$ ) and lower stenosis in DES ( $B = -16.84$ ; 95% confidence interval, -23.55 to -10.13;  $P < .0001$ ).

### Safety Analysis

Safety variables at 1 month are shown in Table 3. Endothelialization was greater with BMS than with DES ( $P = .075$  in the quantitative analysis;  $P = .007$  in the semiquantitative analysis). The results of the injury score were the opposite: there was a lower quantitative value ( $P = .011$ ) and fewer stents with an injury score  $\geq 1$  ( $P < .0001$ ) with DES than with BMS. The degree of inflammation was low for nearly all the stents (less than grade 1). Fibrin deposits were lower in the BMS group than in the tested DES ( $P < .0001$ ). In the individual analysis of the BD1 stent vs BMS, significant differences were found in favor of the BD1 in the injury score and in the degree of inflammation ( $P < .036$  in both cases).

At 3 months, all differences disappeared (Table 4). Vascular injury and inflammation scores were very similar to those



**Figure 3.** Trend in efficacy parameters in stents with data available at 1 month and at 3 months (BMS, DES BD1, and Biomime). BMS, bare-metal stent; DES, drug-eluting stent.

**Table 4**  
Histological Results at 3 Months

	BMS (n = 2)	BD1 (n = 5)	BD3 (n = 5)	Biomime (n = 3)	P <sup>a</sup>
Neointimal area, mm <sup>2</sup>	2.63 ± 1.02	1.07 ± 0.44	1.66 ± 0.40	1.31 ± 0.69	.012
Area of stenosis, %	41.30 ± 7.28	24.68 ± 8.99	38.18 ± 15.29	27.49 ± 12.99	.288
Endothelial area, %	99 ± 1.41	98.50 ± 1.41	98.67 ± 0.94	96.86 ± 1.62	.449
Complete endothelialization > 95%	100	100	80	100	.585
Injury score	0.99 ± 0.12	0.85 ± 0.58	0.64 ± 0.45	0.44 ± 0.30	.366
Injury score ≥ 1	100	20	40	33	.346
Inflammation score	0.68 ± 0.41	0.43 ± 0.24	0.57 ± 0.16	0.52 ± 0.12	.285
Inflammation score ≥ 1	0	0	0	0	–
Fibrin score	0	0.13 ± 0.3	0	0	.699
Fibrin score ≥ 1	0	0	0	0	–

BMS, conventional stent; DES, drug-eluting stent.

Data are expressed as percentage or mean ± standard deviation.

<sup>a</sup> BMS vs DES.

observed at 1 month, with the disappearance of fibrin deposits and almost complete endothelialization.

## DISCUSSION

This study analyzed the safety and efficacy of new biodegradable polymer-based sirolimus-eluting stents compared with BMS and 3 commercially available DES. The preclinical model showed that the new devices decreased the degree of restenosis in a sustained way up to 3 months (particularly BD1) compared with control BMS and with safety parameters equivalent to those of commercially available DES. In certain aspects (inflammation, vascular injury), the new devices were potentially superior to BMS.

### Antirestenotic Efficacy

The new DES generally demonstrated greater efficacy in the prevention of restenosis than control BMS. Previous studies have shown that different biodegradable polymer-based sirolimus-eluting DES significantly decreased late loss and revascularization of the treated vessel compared with BMS<sup>15</sup> and obtained similar results to those of durable-polymer DES.<sup>13–15</sup> Individual analysis showed that BD1 and BD2 stents showed similar and significantly better restenosis values than those of BMS; however, BD3 showed worse values, especially during the 3-month follow-up, and therefore their use was discontinued in the following phases of the study.

The experimental model of healthy coronary arteries was based on the induction of vascular injury by the overdilatation of the stents and, as previously described,<sup>22</sup> a greater degree of injury leads to greater neointimal proliferation. Although the stent/artery ratio in this study was higher than the recommended ratio,<sup>20</sup> it is noteworthy that it was not associated with an excessive injury score that could induce nonspecific vascular responses. Less than 8% of the stents showed a value ≥ 2, without differences between stents. In view of the possible impact of eliminating these data on the overall results, they were included in subsequent analyzes and no relevant variation was observed. In the multivariate analysis, the use of DES was independently associated with a lower degree of stenosis, confirming that the effect is real and is not exclusively related to arterial injury.

### Safety of New Stents

The degree of endothelialization was worse with DES than with control BMS. This response may be explained by the effect of sirolimus, a potent inhibitor of endothelial proliferation via the deactivation of the p70 S6 kinase pathway, which is a fundamental step for cell cycle progression in response to growth factors.<sup>23</sup> Differences between BMS and BD1 were lower than with the overall DES group and did not reach statistical significance ( $P = .121$  in the quantitative analysis;  $P = .055$  in the semiquantitative analysis).

Despite the high stent/artery ratio, all the stents analyzed had low injury scores with a mean value of < 1. Drug-eluting stents showed a significantly lower degree of vascular injury than BMS. Although the stent/artery ratio was similar in both groups ( $1.34 ± 0.19$  vs  $1.30 ± 0.22$ ;  $P = .535$ ), we cannot rule out the possibility that this difference was influenced by some uncontrolled variable. However, this finding also reflects the high degree of biocompatibility of the tested materials.

Likewise, DES tended to show a lower inflammation score ( $P = 0.102$ ) than BMS. In the specific case of BD1 stents, the degree of inflammation and vascular damage were significantly lower ( $P < .036$ ) than with BMS. This finding may be explained by several factors: the anti-inflammatory effect of the drug, the optimized stent design for better drug release, and the contribution of the biodegradable polymer. The inflammation scores were significantly lower than those observed in a previous study with durable-polymer DES.<sup>19</sup> Although it is not possible to make direct comparisons, these findings have already been described in other series.<sup>11,12</sup>

Fibrin deposition around the stents was greater in the DES group, which indicates the effect of the drug.<sup>18,19</sup> As previously mentioned, its disappearance at 3 months is an interesting finding.

In the same way that differences were found between BD1 and BD3, BD2 showed a significantly higher injury score and inflammation scores and worse endothelialization data than BD1. Thus, BD2 was eliminated from the final phases of the study.

### Mid-term Outcome (3 months)

The histological restenosis parameters showed a reduction of the neointimal area and the area of stenosis compared with that observed at 1 month in all stents. This phenomenon has been previously described,<sup>24</sup> although it does not always appear in all DES; in fact, paclitaxel-eluting DES tend to show a greater late

loss.<sup>25</sup> This phenomenon may be explained by the substitution of type III collagen for type I collagen, which causes retraction of the neointima, as in the healing of any injury, and a reduction in the density of smooth muscle cells.<sup>26</sup>

The safety variables showed very favorable 3-month outcomes, with no major inflammation or late vascular damage and with complete endothelialization. The disappearance of fibrin could reflect the rapid release of the drug during this period, as well as the biocompatibility of the polymer.

### Limitations

Like all preclinical models, this study has intrinsic limitations, because no animal model can reproduce with complete fidelity the complex characteristics of human coronary disease.<sup>20</sup> Diseased animal models may reflect some of these characteristics, but their validity remains unverified. Although the activity of the drug and the behavior of the stent can be assessed on the basis of the proliferative response, it is unknown if this effect would be the same in arteries with high atherosclerotic content, in which fragmentation of the internal elastic lamina appears spontaneously as part of the general inflammatory process, particularly in vulnerable plaques, in which other mediators participate in the vascular repair process. Nevertheless, the porcine coronary artery model remains the one recommended by consensus documents for device assessment. Histologic assessment using semiquantitative variables also limits accuracy; however, we followed the standards for analysis recommended by expert consensus.<sup>20</sup> The BMS used was a noncommercial variant of the Architect stent with no specific safety/efficacy information and was used as the basic structure of the DES analyzed. The sample size was small, although it was selected following the standards recommended by the aforementioned consensus documents. Although the power to detect differences with the BMS was adequate, the power to detect differences between DES was lower, and so these comparisons must be interpreted with caution.

### CONCLUSIONS

In an experimental healthy porcine coronary artery model with the implantation of overdilatated stents, new biodegradable polymer-based sirolimus-eluting stents demonstrated a significant reduction in restenosis compared with BMS and this effect was maintained at 3 months. Their safety profile was similar to that of BMS at 3 months. In addition, no relevant differences were found with the biodegradable polymer DES currently available on the market.

### FUNDING

LVD Biotech/Vascular provided all of the study stents and provided financial support for performing the experimental procedures and histologic analyzes.

### CONFLICTS OF INTEREST

A. Pérez de Prado and F. Fernández Vázquez have been consultants and have received support for this research project and others from LVD Biotech/Vascular. M. Molina Crisol, M. Amorós Aguilar, I. Pérez Serranos, A. Vidal Parreu, A. Benavides Montegordo, and L. Duocastella Codina are employees of LVD Biotech/Vascular. L. Duocastella Codina is CEO (Chief Executive Officer) and owns shares in LVD Biotech/Vascular.

### WHAT IS KNOWN ABOUT THE TOPIC?

- Although new-generation DES solve many of the problems of older DES, there is still room for improvement in aspects such as the development of neoatherosclerosis. Progress in the development of drug delivery polymers could help in this task. Before clinical comparisons can be made, new developments must be tested in preclinical models; the healthy porcine coronary artery model remains that recommended by consensus documents to evaluate efficacy and safety.

### WHAT DOES THIS STUDY ADD?

- The analysis of these new biodegradable polymer-based sirolimus-eluting stents demonstrates their sustained efficacy over time (up to 3 months) in the form of lower restenosis (angiographic and histologic) than that found with conventional stents and similar to that found with other commercially available stents. In terms of vascular injury, inflammation, persistent fibrin deposition, and re-endothelialization, their safety is comparable to that of commercially available DES at 1 month and is similar to that of BMS at 3 months.

### REFERENCES

- Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. *N Engl J Med*. 2007;356:989–997.
- Jiménez-Quevedo P, Serrador A, Pérez de Prado A, Pan M. Spanish Cardiac Catheterization and Coronary Intervention Registry. 25th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2015). *Rev Esp Cardiol*. 2016;69:1180–1189.
- Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. *N Engl J Med*. 2007;356:1009–1019.
- Pérez de Prado A, Pérez-Martínez C, Cuellas-Ramón C, et al. Time course of reendothelialization of stents in a normal coronary swine model: characterization and quantification. *Vet Pathol*. 2011;48:1109–1117.
- Pérez de Prado A, Pérez-Martínez C, Cuellas-Ramón C, et al. Scanning Electron Microscopy Analysis of Luminal Inflammation Induced by Different Types of Coronary Stent in an Animal Model. *Rev Esp Cardiol*. 2011;64:159–162.
- Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. *J Am Coll Cardiol*. 2006;48:193–202.
- Pérez de Prado A, Pérez-Martínez C, Cuellas Ramon C, et al. Endothelialization of nonapposed stent struts located over the origin of a side branch: results with different carboxymethylated stents. *J Interv Cardiol*. 2009;22:222–227.
- Pérez de Prado A, Pérez-Martínez C, Cuellas C, et al. Preclinical Evaluation of Coronary Stents: Focus on Safety Issues. *Curr Vasc Pharmacol*. 2013;11:74–99.
- De la Torre Hernández J, Alfonso F, Gimeno F, et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generación-2). *JACC Cardiovasc Interv*. 2010;3:911–919.
- Van Houwelingen KG, Lam MK, Lowik MM, et al. Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial. *Rev Esp Cardiol*. 2016;69:1152–1159.
- Pendyala LK, Matsumoto D, Shinke T, et al. Nobori Stent Shows Less Vascular Inflammation and Early Recovery of endothelial Function Compared With Cypher Stent. *JACC Cardiovasc Interv*. 2012;5:436–444.
- Koppara T, Wittchow E, Byrne RA, Bayer G, Diener T, Joner M. Permanent and biodegradable polymer coatings in the absence of antiproliferative drugs in a porcine model of coronary artery stenting. *EuroIntervention*. 2016;11:1020–1026.
- Saito S, Valdes-Chavarrí M, Richardt G, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. *Eur Heart J*. 2014;35:2021–2031.

14. Kang SH, Park KW, Kang DY, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. *Eur Heart J*. 2014;35:1147–1158.
15. Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. *Lancet*. 2014;384:2111–2122.
16. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. *J Am Coll Cardiol*. 2011;57:1314–1322.
17. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. *J Am Coll Cardiol*. 2004;44:1373–1385.
18. Pérez de Prado A, Pérez-Martínez C, Cuellas Ramón C, et al. Safety and Efficacy of Different Paclitaxel-eluting Balloons in a Porcine Model. *Rev Esp Cardiol*. 2014;67:456–462.
19. Estévez-Loureiro R, Pérez de Prado A, Pérez-Martínez C, et al. Safety and Efficacy of New Sirolimus-eluting Stent Models in a Preclinical Study. *Rev Esp Cardiol*. 2015;68:1118–1124.
20. Schwartz RS, Edelman E, Virmani R, et al. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. *Circ Cardiovasc Interv*. 2008;1:143–153.
21. Byrne RA, Serruys PW, Baumbach A, et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. *Eur Heart J*. 2015;36:2608–2620.
22. Diego A, Perez de Prado A, Cuellas C, et al. In-stent Restenosis Related to Vessel Injury Score Degree. Are Current Experimental Models Valid for Drug-Eluting Stents Analysis? *Rev Esp Cardiol*. 2011;64:745–751.
23. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. *J Am Coll Cardiol*. 2008;52:333–342.
24. Kim WH, Hong MK, Virmani R, Kornowski R, Jones R, Leon MB. Histopathologic analysis of in-stent neointimal regression in a porcine coronary model. *Coron Artery Dis*. 2000;11:273–277.
25. Buszman PP, Milewski K, Pajak J, et al. Differences in vessel healing following delivery of everolimus or paclitaxel: a comparative experimental study using identical stent and biodegradable polymer platforms. *EuroIntervention*. 2014;10:724–731.
26. Farb A, Kolodgie FD, Hwang JY, et al. Extracellular matrix changes in stented human coronary arteries. *Circulation*. 2004;110:940–947.